Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! | Zendy

Shashikant Srivastava | Zendy; Devyani Deshpande | Zendy; Gesham Magombedze | Zendy; Tawanda Gumbo | Zendy

Open Access

Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!

Author(s) -

Shashikant Srivastava,

Devyani Deshpande,

Gesham Magombedze,

Tawanda Gumbo

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy627

Subject(s) - medicine , pyrazinamide , regimen , moxifloxacin , bedaquiline , clofazimine , pharmacokinetics , pharmacology , pharmacodynamics , tuberculosis , population , isoniazid , mycobacterium tuberculosis , confidence interval , antibacterial agent , antibiotics , microbiology and biotechnology , immunology , biology , pathology , leprosy , environmental health

One approach that could increase the efficacy and reduce the duration of antituberculosis therapy is pharmacokinetics/pharmacodynamics-based optimization of doses. However, this could increase toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research